➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
Mallinckrodt
Baxter
Harvard Business School

Last Updated: January 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,188,652

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,188,652 protect, and when does it expire?

Patent 10,188,652 protects DAYVIGO and is included in one NDA.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 10,188,652
Title:Compositions and methods for treating insomnia
Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-- (5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Inventor(s): Moline; Margaret (Woodcliff Lake, NJ), Pastino; Gina (Woodcliff Lake, NJ), Akimoto; Yurie (Kakamigahara, JP), Zaima; Yasuhiro (Kakamigahara, JP), Suzuki; Nobuya (Kakamigahara, JP), Yoshida; Nobuo (Kakamigahara, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:15/519,676
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,188,652

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc DAYVIGO lemborexant TABLET;ORAL 212028-001 Apr 7, 2020 RX Yes No   Start Trial   Start Trial Y   Start Trial
Eisai Inc DAYVIGO lemborexant TABLET;ORAL 212028-002 Apr 7, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,188,652

PCT Information
PCT FiledOctober 21, 2015PCT Application Number:PCT/JP2015/080304
PCT Publication Date:April 28, 2016PCT Publication Number: WO2016/063995

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKinsey
Colorcon
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.